Sai Life Sciences’ Board of Directors approved the unaudited financial results for the quarter and nine months ended December 31, 2025. The company reported a profit of ₹976.30 million for the quarter and ₹2,389.49 million for the nine-month period. The Board also approved the limited review report of the statutory auditors. These results reflect the company’s continued operational performance and financial health.
Financial Performance
Sai Life Sciences announced its unaudited standalone financial results for Q3 2026, with a profit for the quarter standing at ₹976.30 million. The profit for the nine months ended December 31, 2025, totaled ₹2,389.49 million.
Key Financial Figures
Here are some of the key financial highlights from the announcement:
- Revenue from operations for Q3 2026: ₹5,491.79 million
- Total Income for Q3 2026: ₹5,576.26 million
- Profit before tax for Q3 2026: ₹1,304.69 million
- Total Comprehensive Income for Q3 2026: ₹977.18 million
Additional Highlights
The Board of Directors, at its meeting on February 5, 2026, approved the unaudited financial results and noted the limited review report of the statutory auditors, Deloitte Haskins & Sells LLP. During the quarter, the Nomination and Remuneration Committee approved the grant of 205,000 employee stock options.
Source: BSE
